Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Dose (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZM-H1505R

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Dose (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZM-H1505R

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canocapavir (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Zhimeng Biopharma

Most Recent Events

  • 12 Nov 2021 According to a Zhimeng Biopharma media release, the results of this study will be presented in EASLs 2022 International Liver Congress
  • 11 Oct 2021 According to a Zhimeng Biopharma media release, results from this trial will be presented in the upcoming 2021 annual meeting of the America Association for the Study of Liver Diseases (AASLD).
  • 11 Oct 2021 Results published in the Zhimeng Biopharma Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top